INS and type 2 diabetes mellitus: We focused our validation efforts on HMGCR, FDPS and SQLE as these three key drivers participate in the same metabolic pathway-cholesterol biosynthesis- and, in addition, statins (HMGCR inhibitors] are at the center of an intense debate about their effect on insulin resistance and type II diabetes risk [33,41–45].